Impact of Erythropoietin Treatment on the Quality of Life of Oncologic Patients

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2007 Nov 3

PMID 17974525

Citations 1

Authors

A Pelegri

Affiliations

Soon will be listed here.

Abstract

Anaemia has a high incidence in cancer patients, especially when it is a consequence of myelosuppressive treatments. The incidence and prevalence of this condition is influenced by the type and extension of the tumour, type and intensity of the myelosuppressive treatment that patients receive, and previous surgery or intercurrent infections. Clinical manifestations of anaemia, overlapped by tumour symptomatology, depend on haemoglobin (Hb) levels; these manifestations cause impairment of the functional capacity, as well as a negative impact on the quality of life (QOL) of cancer patients as a consequence. Erythropoietin treatment for anaemia has been established as optimal for correcting Hb levels. Its impact on patients' QOL has been evaluated in numerous randomised prospective studies by the use of diverse types of erythropoietin and administration modes. The three types of erythropoietin, alpha, beta and darbepoetin alpha, have shown a clear efficacy in all haematological parameters. This positive effect is related with significant improvements in the QOL of patients, especially those patients undergoing myelosuppressive treatments, and with regard to specific scales of fatigue and anaemia.

Citing Articles

High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008).

Verbeke N, Beguin Y, Wildiers H, Canon J, Bries G, Bosly A Support Care Cancer. 2010; 20(1):23-8.

PMID: 21107613 DOI: 10.1007/s00520-010-1045-0.

References

Witzig T, Silberstein P, Loprinzi C, Sloan J, Novotny P, Mailliard J . Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2004; 23(12):2606-17. DOI: 10.1200/JCO.2004.10.020. View

Yellen S, Cella D, Webster K, Blendowski C, Kaplan E . Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997; 13(2):63-74. DOI: 10.1016/s0885-3924(96)00274-6. View

Knight K, Wade S, Balducci L . Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004; 116 Suppl 7A:11S-26S. DOI: 10.1016/j.amjmed.2003.12.008. View

Ludwig H, Strasser K . Symptomatology of anemia. Semin Oncol. 2001; 28(2 Suppl 8):7-14. DOI: 10.1016/s0093-7754(01)90206-4. View

Jones M, Schenkel B, Just J, Fallowfield L . Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis. Cancer. 2004; 101(8):1720-32. DOI: 10.1002/cncr.20569. View

Gascon P . Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting. Eur J Cancer. 2005; 41(17):2601-12. DOI: 10.1016/j.ejca.2005.04.046. View

Henke M, Laszig R, Rube C, Schafer U, Haase K, Schilcher B . Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362(9392):1255-60. DOI: 10.1016/S0140-6736(03)14567-9. View

Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P . The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004; 40(15):2293-306. DOI: 10.1016/j.ejca.2004.06.019. View

Littlewood T, Bajetta E, Nortier J, Vercammen E, Rapoport B . Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19(11):2865-74. DOI: 10.1200/JCO.2001.19.11.2865. View

10.

Groopman J, Itri L . Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91(19):1616-34. DOI: 10.1093/jnci/91.19.1616. View

11.

Curt G, Breitbart W, Cella D, Groopman J, Horning S, Itri L . Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000; 5(5):353-60. DOI: 10.1634/theoncologist.5-5-353. View

12.

Cella D, Kallich J, McDermott A, Xu X . The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004; 15(6):979-86. DOI: 10.1093/annonc/mdh235. View

13.

Bokemeyer C, Aapro M, Courdi A, Foubert J, Link H, Osterborg A . EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2006; 43(2):258-70. DOI: 10.1016/j.ejca.2006.10.014. View

14.

Bottomley A, Thomas R, Van Steen K, Flechtner H, de Graeff A . Guidelines for the use of epoetin: have quality-of-life benefits been proven?. J Clin Oncol. 2003; 21(11):2223; author reply 2224-5. DOI: 10.1200/JCO.2003.99.208. View

15.

Boogaerts M, Coiffier B, Kainz C . Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer. 2003; 88(7):988-95. PMC: 2376376. DOI: 10.1038/sj.bjc.6600801. View

16.

Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd R . Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol. 2006; 24(15):2290-7. DOI: 10.1200/JCO.2005.03.8570. View

17.

Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C . Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol. 2002; 119(1):79-86. DOI: 10.1046/j.1365-2141.2002.03774.x. View

18.

OShaughnessy J . Chemotherapy-induced cognitive dysfunction: a clearer picture. Clin Breast Cancer. 2004; 4 Suppl 2:S89-94. DOI: 10.3816/cbc.2003.s.021. View

19.

Waltzman R, Croot C, Justice G, Fesen M, Charu V, Williams D . Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist. 2005; 10(8):642-50. DOI: 10.1634/theoncologist.10-8-642. View

20.

Savonije J, Van Groeningen C, van Bochove A, Honkoop A, van Felius C, Wormhoudt L . Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. Eur J Cancer. 2005; 41(11):1560-9. DOI: 10.1016/j.ejca.2005.03.024. View